As a manner to enhance the standard of an infection testing and obtain higher affected person outcomes, Amedisys Inc. (Nasdaq: AMED) now gives superior molecular testing at its healthcare facilities throughout the nation.

To attain this, the corporate is working with Affected person Selection Laboratories to higher establish respiratory issues, wound infections and different circumstances in dwelling sufferers.

“This new partnership will enable our physicians to actually have extra management over our sufferers' outcomes,” Barbara Andazola, VP of medical apply, technique and packages at Amedisys, instructed House Well being Care Information. “It isn’t with out cause that a big a part of our focus is on decreasing hospitalization charges for our sufferers. By empowering our care groups to offer well timed and extra correct remedy plans, we’re optimistic that implementation of those new practices will finally cut back the influence of infections and ship higher outcomes.”

Baton Rouge, Louisiana-based Amedisys is a house well being care firm with operations in 37 states and the District of Columbia. The corporate gives dwelling well being and hospice companies, in addition to excessive acuity companies within the dwelling by means of its subsidiary Contessa Well being.

Andazola stated she and her group had been in discussions with Affected person Selection Laboratories for a while, particularly as sufferers have develop into extra complicated.

“It's additionally one thing that feels comparatively new to our referral companions,” Andazola stated. “The flexibility to get real-time outcomes and make knowledgeable selections is absolutely essential as a result of what would possibly beforehand have taken 4 or 5 days can now occur on the identical day. Exhibiting that the added worth for our healthcare suppliers and referral companions isn’t solely helpful to sufferers, but in addition aligns with our broader targets.”

Normally, superior molecular testing refers to a sophisticated diagnostic method that analyzes genetic materials to detect pathogens or particular genetic markers related to ailments.

The tactic, Andazola explains, goals to offer quick and correct outcomes that can enable Amedisys to establish infectious pathogens with better accuracy, sensitivity and specificity in comparison with conventional testing strategies.

It additionally helps with workflow, Andazola stated. Amedisys, like all suppliers, nonetheless faces staffing points. Nevertheless, any effectivity enhancements from an innovation and know-how perspective can alleviate among the workforce shortages.

By shortening the time it takes for a doctor to make an evaluation primarily based on an infection and molecular testing, Amedisys group members can spend extra time caring for his or her sufferers.

“Our automated pre-analytical, analytical and post-analytical processes in molecular applied sciences present the required medical choice assist in order that therapies are focused and profitable,” stated Brad Moss, president of Sufferers Selection Laboratories, in a press release.